LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: Can beta-adrenergic blockers be used in the treatment of COVID-19?

    Vasanthakumar, Natesan

    Medical hypotheses

    2020  Volume 142, Page(s) 109809

    MeSH term(s) Adrenergic beta-Antagonists/pharmacology ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/pathogenicity ; Betacoronavirus/physiology ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/physiopathology ; Coronavirus Infections/virology ; Humans ; Models, Biological ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/physiopathology ; Pneumonia, Viral/virology ; Renin-Angiotensin System/drug effects ; SARS-CoV-2 ; Virus Internalization/drug effects
    Chemical Substances Adrenergic beta-Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Keywords covid19
    Language English
    Publishing date 2020-05-05
    Publishing country United States
    Document type Letter
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109809
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients.

    Vasanthakumar, Natesan

    BioEssays : news and reviews in molecular, cellular and developmental biology

    2020  Volume 42, Issue 11, Page(s) e2000094

    Abstract: More than 15 million people have been affected by coronavirus disease 2019 (COVID-19) and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID-19 patients. Though many drugs have been proposed, ...

    Abstract More than 15 million people have been affected by coronavirus disease 2019 (COVID-19) and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID-19 patients. Though many drugs have been proposed, none of them has shown particular efficacy in clinical trials. In this article, the relationship between the Adrenergic system and the renin-angiotensin-aldosterone system (RAAS) is focused in COVID-19 and a vicious circle consisting of the Adrenergic system-RAAS-Angiotensin converting enzyme 2 (ACE2)-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (which is referred to as the "ARAS loop") is proposed. Hyperactivation of the ARAS loop may be the underlying pathophysiological mechanism in COVID-19, and beta-adrenergic blockers are proposed as a potential treatment option. Beta-adrenergic blockers may decrease the SARS-CoV-2 cellular entry by decreasing ACE2 receptors expression and cluster of differentiation 147 (CD147) in various cells in the body. Beta-adrenergic blockers may decrease the morbidity and mortality in COVID-19 patients by preventing or reducing acute respiratory distress syndrome (ARDS) and other complications. Retrospective and prospective clinical trials should be conducted to check the validity of the hypothesis. Also see the video abstract here https://youtu.be/uLoy7do5ROo.
    MeSH term(s) Adrenergic beta-Antagonists/pharmacology ; Adrenergic beta-Antagonists/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Betacoronavirus/drug effects ; Betacoronavirus/physiology ; COVID-19 ; Carvedilol/pharmacology ; Carvedilol/therapeutic use ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Papain-Like Proteases ; Drug Repositioning/methods ; Humans ; Inflammasomes/drug effects ; Inflammasomes/metabolism ; Inflammation Mediators/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Pandemics ; Papain/antagonists & inhibitors ; Papain/metabolism ; Peptidyl-Dipeptidase A/drug effects ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Protease Inhibitors/pharmacology ; Protease Inhibitors/therapeutic use ; Pulmonary Embolism/prevention & control ; Renin-Angiotensin System/drug effects ; Renin-Angiotensin System/physiology ; Respiratory Insufficiency/prevention & control ; SARS-CoV-2 ; Shock, Septic/prevention & control ; Viral Nonstructural Proteins/antagonists & inhibitors ; Viral Nonstructural Proteins/metabolism ; Virus Internalization/drug effects
    Chemical Substances Adrenergic beta-Antagonists ; Inflammasomes ; Inflammation Mediators ; NLR Family, Pyrin Domain-Containing 3 Protein ; NLRP3 protein, human ; Protease Inhibitors ; Viral Nonstructural Proteins ; Carvedilol (0K47UL67F2) ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Coronavirus Papain-Like Proteases (EC 3.4.22.2) ; Papain (EC 3.4.22.2) ; papain-like protease, SARS-CoV-2 (EC 3.4.22.2)
    Keywords covid19
    Language English
    Publishing date 2020-09-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 50140-2
    ISSN 1521-1878 ; 0265-9247
    ISSN (online) 1521-1878
    ISSN 0265-9247
    DOI 10.1002/bies.202000094
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2024: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Beta‐Adrenergic Blockers as a Potential Treatment for COVID‐19 Patients

    Vasanthakumar, Natesan

    BioEssays

    2020  Volume 42, Issue 11, Page(s) 2000094

    Keywords General Biochemistry, Genetics and Molecular Biology ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 50140-2
    ISSN 1521-1878 ; 0265-9247
    ISSN (online) 1521-1878
    ISSN 0265-9247
    DOI 10.1002/bies.202000094
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2024: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Can beta-adrenergic blockers be used in the treatment of COVID-19?

    Vasanthakumar, Natesan

    Medical Hypotheses

    2020  Volume 142, Page(s) 109809

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109809
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book ; Online: SARS-CoV-2 host cell entry might involve Beta adrenergic receptors

    Natesan, Vasanthakumar

    2020  

    Abstract: Coronavirus disease 2019 (COVID-19) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 enters the host cell by binding its spike protein with the angiotensin-converting enzyme 2 (ACE2) receptor. Cluster of ... ...

    Abstract Coronavirus disease 2019 (COVID-19) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 enters the host cell by binding its spike protein with the angiotensin-converting enzyme 2 (ACE2) receptor. Cluster of differentiation 147 (CD147) also known as Basigin or extracellular matrix metalloproteinase inducer (EMMPRIN), has been proposed as another host cell receptor that might be involved in SARS-CoV-2 cellular entry . Any other host cell receptors that exist for SARS-CoV-2 is not known at present. I suggest that the Beta adrenergic receptor might be involved in the SARS-CoV-2 cell entry, and act as a co-receptor by its interaction via surface vimentin to the ACE2 receptor and by forming a complex with CD147.
    Keywords covid19
    Publisher Center for Open Science
    Publishing country us
    Document type Book ; Online
    DOI 10.31219/osf.io/d2g8k
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Book ; Online: Adrenergic storm-induced Warburg effect in COVID-19

    Natesan, Vasanthakumar

    A hypothesis.

    2020  

    Abstract: At present, there is no treatment option available for COVID-19 condition and most importantly the underlying pathophysiology in COVID-19 is not known. No theory at present explains all the clinical features in COVID-19. In this article, I had proposed a ...

    Abstract At present, there is no treatment option available for COVID-19 condition and most importantly the underlying pathophysiology in COVID-19 is not known. No theory at present explains all the clinical features in COVID-19. In this article, I had proposed a hypothesis that explains the underlying pathophysiology in COVID-19 and based on it proposed treatment options for COVID-19. I propose that the adrenergic storm-induced Warburg effect (aerobic glycolysis) may be the underlying mechanism in the COVID-19 condition. I propose alpha1 adrenergic blockers in the early phase and beta-adrenergic blockers in the late phase of COVID-19 to inhibit the adrenergic storm and reverse the Warburg effect in COVID-19 condition.
    Keywords covid19
    Publisher Center for Open Science
    Publishing country us
    Document type Book ; Online
    DOI 10.31219/osf.io/z654v
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Book ; Online: Can beta-adrenergic blockers be used in the treatment of COVID-19?

    Natesan, Vasanthakumar

    2020  

    Abstract: At present, there is no specific treatment available for COVID-19 patients. I propose that re-purposing the beta-adrenergic blockers for treating COVID-19 patients may be beneficial. This drug may decrease the ACE2 receptors which are used by the SARS- ... ...

    Abstract At present, there is no specific treatment available for COVID-19 patients. I propose that re-purposing the beta-adrenergic blockers for treating COVID-19 patients may be beneficial. This drug may decrease the ACE2 receptors which are used by the SARS-COV-2 Virus to enter the cell. Also 1 to 3% of the COVID-19 patients develop complications like ARDS and Septic shock. Beta-adrenergic blockers has been already shown to decrease mortality rate in these conditions. In a nutshell, beta-adrenergic blockers will decrease the SARS-COV-2 virus entry in to the cell and also decrease the mortality in the severely affected patients.A retrospective study has been proposed to check the validity of the hypothesis. This idea has the potential to save millions of lives.
    Keywords covid19
    Publisher Center for Open Science
    Publishing country us
    Document type Book ; Online
    DOI 10.31219/osf.io/sjdmk
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Book ; Online: Beta-adrenergic blocker treatment for COVID-19

    Natesan, Vasanthakumar

    2020  

    Abstract: More than 2.5 million people were affected by COVID-19 and it had caused around 175000 deaths as of April 23, 2020. Currently no effective treatment option is present for COVID-19 patients. Even though many drugs have been proposed, none of them showed ... ...

    Abstract More than 2.5 million people were affected by COVID-19 and it had caused around 175000 deaths as of April 23, 2020. Currently no effective treatment option is present for COVID-19 patients. Even though many drugs have been proposed, none of them showed its efficacy in clinical trials. In this article, I had briefly reviewed the current scenario of COVID-19 condition, and focused on the Adrenergic system- RAAS relation in COVID-19 and proposed a vicious Adrenergic system-RAAS-ACE2-SARS-CoV-2 (ARAS) loop. Hyperactivation of ARAS loop may be the underlying pathophysiological mechanism in COVID-19. I had proposed beta-adrenergic blockers as a potential treatment option for treating COVID-19. Beta-adrenergic blockers by its negative regulation of RAAS pathway may decrease ACE2 receptors expression and CD147 in various cells in the body including typeII pulmonary alveolar epithelial cells and decrease the SARS-CoV-2 virus cellular entry. Beta-adrenergic blocker may also exert beneficial affects through inhibition of NLRP3 inflammasome, and reduction of proinflammatory cytokines like IL-6, reduced expression of MUC5AC, and decreasing airway mucus secretion. Beta-adrenergic blockers may decrease the morbidity and mortality in COVID-19 patients by preventing or reducing the ARDS, pulmonary embolism, pulmonary edema, refractory hypoxemia, and Septic shock complications. Considering potential beneficial effects of beta-adrenergic blockers in COVID-19, retrospective and prospective clinical trials needs to conducted to check the validity of the hypothesis and clarify its role in COVID-19. I had speculated that Beta2-adrenergic agonists use in the nebulizers and norepinephrine use in the COVID-19 patients having septic shock may worsen the condition. I suggest that Beta-adrenergic blockers should be used in the treatment of COVID-19, and norepinephrine, beta2-adrenergic agonists should be avoided in COVID-19.
    Keywords covid19
    Publisher Center for Open Science
    Publishing country us
    Document type Book ; Online
    DOI 10.31219/osf.io/wdp4g
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients

    Vasanthakumar, Natesan

    Bioessays

    Abstract: More than 15 million people have been affected by coronavirus disease 2019 (COVID-19) and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID-19 patients. Though many drugs have been proposed, ...

    Abstract More than 15 million people have been affected by coronavirus disease 2019 (COVID-19) and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID-19 patients. Though many drugs have been proposed, none of them has shown particular efficacy in clinical trials. In this article, the relationship between the Adrenergic system and the renin-angiotensin-aldosterone system (RAAS) is focused in COVID-19 and a vicious circle consisting of the Adrenergic system-RAAS-Angiotensin converting enzyme 2 (ACE2)-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (which is referred to as the "ARAS loop") is proposed. Hyperactivation of the ARAS loop may be the underlying pathophysiological mechanism in COVID-19, and beta-adrenergic blockers are proposed as a potential treatment option. Beta-adrenergic blockers may decrease the SARS-CoV-2 cellular entry by decreasing ACE2 receptors expression and cluster of differentiation 147 (CD147) in various cells in the body. Beta-adrenergic blockers may decrease the morbidity and mortality in COVID-19 patients by preventing or reducing acute respiratory distress syndrome (ARDS) and other complications. Retrospective and prospective clinical trials should be conducted to check the validity of the hypothesis. Also see the video abstract here https://youtu.be/uLoy7do5ROo.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #723430
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top